ReviewCritical reviews in oncogenesis2016
Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
Review in Critical reviews in oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 187 citations in OpenAlex.
- Sarcoma metastasis: distinct biological principles beyond the carcinoma paradigm.Cancer metastasis reviews · 2026Review
- ITGA5 as a Dual Regulator of Epithelial-Mesenchymal Transition and Epithelial Cell Anoikis Resistance: Functional Validation and Drug Prediction.Cell proliferation · 2026Article
- Pancreatic cancer EMT‑targeted therapy: Molecular mechanisms and clinical translation (Review).International journal of oncology · 2026Review
- Role and Mechanism ofInternational journal of molecular sciences · 2026Article
- Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026Review
- Lactoferrin inhibits anoikis-resistance and metastasis of nasopharyngeal carcinoma cells via the AKT signaling pathway.International journal of clinical and experimental pathology · 2026Article
- Epigenetic alterations in cancer metastasis: molecular mechanisms and implications for precision oncology.Frontiers in oncology · 2026Review
- Anoikis-related genes predicts prognosis and therapeutic response in renal cell carcinoma.Annals of medicine · 2025Article
- The integrin-matrix-FAK-EMT axis in Anoikis resistance: a critical network in tumor progression and therapy.Molecular biology reports · 2025Review
- Prognostic value of anoikis- and epithelial-mesenchymal transition-related genes and development of a prognostic risk model in thyroid cancer.Discover oncology · 2025Article
- Anoikis resistance and cancer.BMC cancer · 2025Review
- Adipocytes promoted anoikis resistance of head and neck cancer cells via overexpressed ITGA5.European journal of medical research · 2025Article
- Emerging roles and therapeutic potential of non-coding RNA in osteosarcoma: a review.Medical oncology (Northwood, London, England) · 2025Review
- BUB1-based risk model predicts prostate cancer prognosis and reveals therapeutic vulnerabilities.European journal of medical research · 2025Article
- Article
- A novel anoikis related gene prognostic model for colorectal cancer based on single cell sequencing and bulk transcriptome analyses.Scientific reports · 2025Article
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer letters · 2025Review
- Review
- Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival.Cell biology and toxicology · 2025Article
- Hypoxia signaling in cancer: HIF-1α stimulated by COVID-19 can lead to cancer progression and chemo-resistance in oral squamous cell carcinoma (OSCC).Discover oncology · 2025Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Anoikis is a unique mode of apoptotic cell death that occurs consequentially to insufficient cell-matrix interactions. Resistance to anoikis is a critical contributor to tumor invasion and metastasis. The phenomenon is regulated by integrins, which upon engagement with components of the extracellular matrix (ECM) form adhesion complexes and the actin cytoskeleton drives the formation of cell protrusions used to adhere to ECM, directing cell migration. The epithelial-mesenchymal transition (EMT) confers stem cell properties and leads to acquisition of a migratory and invasive phenotype by causing adherens junction breakdown and circumventing anoikis in the tumor microenvironment. The investigation of drug discovery platforms for apoptosis-driven therapeutics identified several novel agents with antitumor action via reversing resistance to anoikis, inhibiting survival pathways and impacting the EMT landscape in human cancer. In this review, we discuss current evidence on the contribution of the anoikis phenomenon functionally linked to EMT to cancer metastasis and the therapeutic value of antitumor drugs that selectively reverse anoikis resistance and/or EMT to impair tumor progression toward the development/optimization of apoptosis-driven therapeutic targeting of metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.